These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Identification of small molecules that inhibit GSK-3beta through virtual screening. Kang NS; Lee GN; Kim CH; Bae MA; Kim I; Cho YS Bioorg Med Chem Lett; 2009 Jan; 19(2):533-7. PubMed ID: 19081248 [TBL] [Abstract][Full Text] [Related]
24. Biological evaluation and energetic analyses of novel GSK-3β inhibitors. Zhang D; Liu L; Pang L; Jin Q; Ke K; Hu M; Yang J; Ma W; Xie H; Chen X J Cell Biochem; 2018 Apr; 119(4):3510-3518. PubMed ID: 29144001 [TBL] [Abstract][Full Text] [Related]
25. Probing novel 1-aza-9-oxafluorenes as selective GSK-3beta inhibitors. Voigt B; Krug M; Schächtele C; Totzke F; Hilgeroth A ChemMedChem; 2008 Jan; 3(1):120-6. PubMed ID: 18000938 [TBL] [Abstract][Full Text] [Related]
26. Development of [ Jia J; Yi L; Xia Z; Yang M; Qiu D; Zhao Z; Peng Z Bioorg Med Chem Lett; 2023 May; 88():129263. PubMed ID: 37004924 [TBL] [Abstract][Full Text] [Related]
27. Novel Zhong Y; Yang S; Cui J; Wang J; Li L; Chen Y; Chen J; Feng P; Huang S; Li H; Han Y; Tang G; Hu K Mol Pharm; 2021 Mar; 18(3):1277-1284. PubMed ID: 33492962 [TBL] [Abstract][Full Text] [Related]
28. Glycogen synthase kinase-3β regulates fractalkine production by altering its trafficking from Golgi to plasma membrane: implications for Alzheimer's disease. Fuster-Matanzo A; Jurado-Arjona J; Benvegnù S; García E; Martín-Maestro P; Gómez-Sintes R; Hernández F; Ávila J Cell Mol Life Sci; 2017 Mar; 74(6):1153-1163. PubMed ID: 27832289 [TBL] [Abstract][Full Text] [Related]
29. Identifying GSK-3β kinase inhibitors of Alzheimer's disease: Virtual screening, enzyme, and cell assays. Lin CH; Hsieh YS; Wu YR; Hsu CJ; Chen HC; Huang WH; Chang KH; Hsieh-Li HM; Su MT; Sun YC; Lee GC; Lee-Chen GJ Eur J Pharm Sci; 2016 Jun; 89():11-9. PubMed ID: 27094783 [TBL] [Abstract][Full Text] [Related]
30. A physicochemical descriptor based method for effective and rapid screening of dual inhibitors against BACE-1 and GSK-3β as targets for Alzheimer's disease. Kumar A; Srivastava G; Sharma A Comput Biol Chem; 2017 Dec; 71():1-9. PubMed ID: 28950235 [TBL] [Abstract][Full Text] [Related]
31. First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. Martinez A; Alonso M; Castro A; Pérez C; Moreno FJ J Med Chem; 2002 Mar; 45(6):1292-9. PubMed ID: 11881998 [TBL] [Abstract][Full Text] [Related]
32. Direct determination of GSK-3β activity and inhibition by UHPLC-UV-vis diode arrays detector (DAD). D'Urzo A; De Simone A; Fiori J; Naldi M; Milelli A; Andrisano V J Pharm Biomed Anal; 2016 May; 124():104-111. PubMed ID: 26942334 [TBL] [Abstract][Full Text] [Related]
33. Diabetes mellitus and Alzheimer's disease: GSK-3β as a potential link. Zhang Y; Huang NQ; Yan F; Jin H; Zhou SY; Shi JS; Jin F Behav Brain Res; 2018 Feb; 339():57-65. PubMed ID: 29158110 [TBL] [Abstract][Full Text] [Related]
34. Novel benzothiazinones (BTOs) as allosteric modulator or substrate competitive inhibitor of glycogen synthase kinase 3β (GSK-3β) with cellular activity of promoting glucose uptake. Zhang P; Li S; Gao Y; Lu W; Huang K; Ye D; Li X; Chu Y Bioorg Med Chem Lett; 2014 Dec; 24(24):5639-5643. PubMed ID: 25467150 [TBL] [Abstract][Full Text] [Related]
35. Loss of biliverdin reductase-A favors Tau hyper-phosphorylation in Alzheimer's disease. Sharma N; Tramutola A; Lanzillotta C; Arena A; Blarzino C; Cassano T; Butterfield DA; Di Domenico F; Perluigi M; Barone E Neurobiol Dis; 2019 May; 125():176-189. PubMed ID: 30738142 [TBL] [Abstract][Full Text] [Related]
36. Dual-target inhibitors of cholinesterase and GSK-3β to modulate Alzheimer's disease. He J; Tam KY Drug Discov Today; 2024 Apr; 29(4):103914. PubMed ID: 38340951 [TBL] [Abstract][Full Text] [Related]
37. Discovery of thiazolidin-4-one analogue as selective GSK-3β inhibitor through structure based virtual screening. Choudhary BS; Sukanya ; Mehta P; Bach S; Ruchaud S; Robert T; Josselin B; Filipek S; Malik R Bioorg Med Chem Lett; 2021 Nov; 52():128375. PubMed ID: 34560262 [TBL] [Abstract][Full Text] [Related]
38. Glycogen synthase kinase-3beta is activated by matrix metalloproteinase-2 mediated proteolysis in cardiomyoblasts. Kandasamy AD; Schulz R Cardiovasc Res; 2009 Sep; 83(4):698-706. PubMed ID: 19493954 [TBL] [Abstract][Full Text] [Related]
39. Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25. Leost M; Schultz C; Link A; Wu YZ; Biernat J; Mandelkow EM; Bibb JA; Snyder GL; Greengard P; Zaharevitz DW; Gussio R; Senderowicz AM; Sausville EA; Kunick C; Meijer L Eur J Biochem; 2000 Oct; 267(19):5983-94. PubMed ID: 10998059 [TBL] [Abstract][Full Text] [Related]
40. Role of GSK-3β Inhibitors: New Promises and Opportunities for Alzheimer's Disease. Shri SR; Manandhar S; Nayak Y; Pai KSR Adv Pharm Bull; 2023 Nov; 13(4):688-700. PubMed ID: 38022801 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]